Advancing Characterization Testing, Biomarker Discovery & Streamlined Logistics for Donor-Derived Material to Meet Clinical Demand for Allogeneic Therapies
How far can the allogeneic cell therapy field progress without high-quality starting material and robust donor selection processes?
The 3rd Donor Selection & Cell Source Summit returned to San Diego last November to address these key challenges.
As the leading platform for allogeneic biopharma, academia, starting material suppliers, and other service providers, this summit brought together key stakeholders to share insights on navigating the challenges of consistency, safety, and efficacy when using donor-derived starting material. It also drove forward new approaches to recruitment and retention, with the shared goal of ensuring a consistent and reliable supply of starting material required for clinical trials.
2025 Official Partners
Attending Companies Included